Hls Therapeutics, Inc. · TSX:HLS
Hls Therapeutics — H.C. Wainwright 25th Annual Global Investment Conference (September 2023)
21 slides from Hls Therapeutics's conference presentation, Sep 12, 2023
Slide 1: Investor Presentation | September 2023
Investor Presentation | September 2023 TSX - HLS
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not alwa
Slide 3: New leadership
New leadership Driving operational effectiveness Poised for organic growth Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update 3
Slide 4: HLS is a North American Commercially-Focused Pharmaceutical Company
HLS is a North American Commercially-Focused Pharmaceutical Company 2 THERAPEUTIC AREAS: Neuroscience Cardiovascular Foundation of cash flow generating assets combined with Montreal significant organic growth potential Toronto (HQ) Philadelphia US$ 61.5M US$ 23.8M C$ 150M 2022 Revenue 2022 Adj. EBIT
Slide 5: Life-changing medicine for Treatment Resistant Schizophrenia
NEUROSCIENCE Life-changing medicine for Treatment Resistant Schizophrenia Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 6: Clozaril (Clozapine): A Life Changing Medicine
Clozaril (Clozapine): A Life Changing Medicine ~3.3M 1/3 The Only Approved Treatment for TRS Americans & of all patients with • 60% response rate2 with TRS patients ~400,000 schizophrenia have treatment-resistant • On the WHO’s list of essential medicines Canadians are living schizophrenia (TRS)1 •
Slide 7: CSAN Patient Support Platform is Our Competitive Advantage
CSAN Patient Support Platform is Our Competitive Advantage The Clozaril Support & DEDICATED TEAM: Assistance Network (CSAN) Nurse Educators supports prescribers & patients Clinical Coordinators Physician Consultants Patients enrolled in CSAN have a compliance rate 32% INNOVATIVE TECH: higher tha
Slide 8: Consistent Brand Performance Generates Stable Cash Flow
Consistent Brand Performance Generates Stable Cash Flow US$42.2M US$32.7M 8 Revenue 2022 Direct contribution to consecutive years Adjusted EBITDA 2022 of patient growth in Canada since acquired by HLS Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such,
Slide 9: A New Paradigm in the Treatment of Cardiovascular Risk
CARDIOVASCULAR A New Paradigm in the Treatment of Cardiovascular Risk Toronto Stock Exchange (TSX) - HLS
Slide 10: Cardiovascular Disease is a Leading Cause of Death
Cardiovascular Disease is a Leading Cause of Death ~3M Canadians on statins with diagnosed heart disease and/or diabetes1 Significant CV risk remains Statins reduce risk of a major CV event by 15-44%2 With CV With With CV disease diabetes disease and diabetes 1 HLS estimate based on Statistics Canad
Slide 11: Reduce-IT: Landmark Clinical Study
Reduce-IT: Landmark Clinical Study CRITERIA: RESULTS: EVAPORATE TRIAL: 8,200 statin-treated patients Relative Risk Reduction in major Vascepa patients showed 11 countries adverse CV events in patients on a 17% reduction in low- 5-year trial in: statin treatment1 attenuation plaque over Patients wh
Slide 12: Significant Near-Term Growth Potential
Significant Near-Term Growth Potential Reimbursement in place: • >90% private payer coverage ~800,000 Canadians1 in-label • >70% public payer coverage with access to reimbursement 25 international medical societies or journals recommend the use of Vascepa C$1B+ Total Addressable Market Portfolio of
Slide 13: Strong Prescription Momentum
Strong Prescription Momentum Weekly script data since launch 2000 1,877 1800 91% increase 1600 in total prescriptions* 1400 1200 1000 96% increase in prescribers* 800 600 400 139% increase 200 in consistent prescribers* 0 (*Q2 2023 compared to Q2 2022) Jun-20 Jun-21 Jun-22 Jun-23 Oct-20 Oct-21 Oct-2
Slide 14: Drive Growth & Accelerate the Path to Profitability
Drive Growth & Accelerate the Path to Profitability Adapt go-to-market • Focused sales force effort on specialists & promotionally-responsive GPs 1 model • Augment with cost-effective multi-channel marketing Improve reimbursement • Reduce administrative burden for physician practices 2 dynamics • Im
Slide 15: Financial Strength: Solid Foundation to support our growth
Financial Strength: Solid Foundation to support our growth Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 16: Cash-Flow Generating Assets and Organic Growth
Cash-Flow Generating Assets and Organic Growth Annual Vascepa Revenue (CDN$ M) % change % change (USD$ (constant YTD (constant millions) FY 2022 % change currency) 2023 % change currency) Product 51.7 +2% +4.5% 25.0 0% +4% TARGET: $18-$20M REVENUE Royalty 9.8 +4% +4% 6.2 +24% +24% Total 61.5 +2% +5%
Slide 17: Vascepa to Become a Positive Contributor to Adjusted EBITDA
Vascepa to Become a Positive Contributor to Adjusted EBITDA Adjusted EBITDA Contribution ACTUAL (H1 2023) OUTLOOK (H2 2024) Vascepa to generate positive contribution to Adjusted EBITDA in 2H 2024 direct contribution to continued strong Adjusted EBITDA: contribution to Adjusted EBITDA $14.4M direct c
Slide 18: Strong Balance Sheet with Capacity for Expansion
Strong Balance Sheet with Capacity for Expansion Summary Balance Sheet & Capitalization Share Buyback (US$ millions) At Dec 31, 2022 At Jun 30, 2023 • Return of capital via NCIB (share buyback) • 4x increase in July/August over prior year period Cash and Cash Equivalents 20.7 20.9 1 Senior Secured T
Slide 19: Management and Board of Directors
MANAGEMENT BOARD OF DIRECTORS Craig Millian, MBA John Welborn, Chair of the Board Chief Executive Officer Senior Advisor, Stadium Capital Management, LLC Tim Hendrickson, MBA Craig Millian, Chief Executive Officer Chief Financial Officer Laura A. Brege Brian T. Walsh, MBA Managing Director, Cervante
Slide 20: Stable cash flow & significant organic growth potential
Stable cash flow & significant organic growth potential Near-term operational catalysts for Vascepa Improved promotional effectiveness Enhanced reimbursement Target positive Adj. EBITDA in 2H 2024 ~4x increase in share buy-back Financial capacity for future expansion Toronto Stock Exch
Slide 21: Investor Presentation | September 2023
Investor Presentation | September 2023 TSX - HLS
HLS Therapeutics — H.C. Wainwright 25th Annual Global Investment Conference (September 2023) on 6ix